Benefits of nonionic contrast in coronary arteriography: Preliminary results of a randomized double-blind trial comparing iopamidol with renografin-76

Allen A. Ciuffo, Richard M. Fuchs, Pablo A. Guzman, Kenneth P. Brin, Dean E. Kross, James L. Weiss, Robin W. Feroli, Jeffrey A. Brinker

Research output: Contribution to journalArticlepeer-review

Abstract

The cardiovascular effects of the commonly used ionic contrast, 76% sodium meglumine diatrizoate (Renografin-76) and iopamidol, a new nonionic contrast agent, were compared in a randomized, double-blind crossover study of 17 patients undergoing coronary arteriography. Intracoronary injection of iopamidol resulted in less depression of systemic blood pressure (4% versus 13%) P < 0.001, heart rate (4% versus 26%) P < 0.01, and left ventricular contractility, P < 0.03, than Renografin-76. In addition, intracoronary iopamidol prolonged the QT interval less (23% versus 2%)P = 0.001 and resulted in less alteration in the electrocardiographic T-wave amplitude (60% versus 153%) P = 0.001 than Renografin-76. The two agents had similar effects on coronary blood flow and resulted in studies of uniformly good quality. Thus, iopamidol appears to be a safer contrast agent for use in coronary arteriography than the prototypic ionic contrast agent, Renografin-76.

Original languageEnglish (US)
Pages (from-to)S197-S202
JournalInvestigative radiology
Volume19
Issue number5
StatePublished - Jan 1 1984

Keywords

  • Contrast toxicity
  • Coronary arteriography
  • Iopamidol
  • Renografin-76

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Benefits of nonionic contrast in coronary arteriography: Preliminary results of a randomized double-blind trial comparing iopamidol with renografin-76'. Together they form a unique fingerprint.

Cite this